Form 4: Castle Biosciences CFO Frank Stokes Sells Shares Under 10b5-1 Plan
SEC Form 4
Frank Stokes, CFO of Castle Biosciences, sold a total of 10,000 shares of common stock on August 7, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On August 7, 2024, Frank Stokes, the Chief Financial Officer of Castle Biosciences, sold 4,600 shares of common stock at a weighted average price of $25.197.
- He also sold 5,400 shares of common stock at a weighted average price of $26.128.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on May 6, 2024.
- Following these sales, Stokes directly owns 30,823 shares of Castle Biosciences common stock, which includes 1,272 shares acquired on February 29, 2024, under the Issuer's employee stock purchase plan.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine stock sales under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Insider selling is a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares in a pre-planned manner to avoid accusations of trading on non-public information. It is important to monitor insider transactions as they can provide insights into management's perspective on the company's valuation and future prospects.
Stakeholder Impact
- Shareholders may interpret insider selling in various ways, potentially leading to price fluctuations.
- The impact on employees, customers, suppliers, and creditors is likely minimal unless the selling activity is perceived as a sign of deeper issues within the company.
Key Dates
| Date | Description |
|---|---|
| 2024-02-29 | Stokes acquired 1,272 shares under the Issuer's employee stock purchase plan. |
| 2024-05-06 | Frank Stokes adopted a Rule 10b5-1 plan. |
| 2024-08-07 | Frank Stokes sold 4,600 shares of common stock at a weighted average price of $25.197. |
| 2024-08-07 | Frank Stokes sold 5,400 shares of common stock at a weighted average price of $26.128. |
| 2024-08-13 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.